Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
11.07
+0.33 (3.07%)
At close: Feb 21, 2025, 4:00 PM
11.20
+0.13 (1.17%)
After-hours: Feb 21, 2025, 7:45 PM EST
Arcus Biosciences Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Arcus Biosciences stock have an average target of 31.11, with a low estimate of 17 and a high estimate of 50. The average target predicts an increase of 181.03% from the current stock price of 11.07.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Arcus Biosciences stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 4 | 4 | 3 |
| Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 12 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Hold Maintains $22 → $17 | Hold | Maintains | $22 → $17 | +53.57% | Feb 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $20 → $18 | Hold | Maintains | $20 → $18 | +62.60% | Feb 18, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $36 → $25 | Buy | Maintains | $36 → $25 | +125.84% | Feb 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $20 | Hold | Reiterates | $20 | +80.67% | Nov 6, 2024 |
| Barclays | Barclays | Buy Maintains $25 → $29 | Buy | Maintains | $25 → $29 | +161.97% | Oct 25, 2024 |
Financial Forecast
Revenue This Year
266.35M
from 117.00M
Increased by 127.65%
Revenue Next Year
215.68M
from 266.35M
Decreased by -19.02%
EPS This Year
-3.47
from -4.15
EPS Next Year
-4.92
from -3.47
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 285.6M | 606.2M | 540.8M | |||
| Avg | 266.4M | 215.7M | 232.2M | |||
| Low | 239.1M | 29.4M | 88.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 144.1% | 127.6% | 150.7% | |||
| Avg | 127.6% | -19.0% | 7.7% | |||
| Low | 104.4% | -89.0% | -59.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.57 | -3.56 | -1.93 | |||
| Avg | -3.47 | -4.92 | -4.50 | |||
| Low | -4.06 | -6.60 | -6.08 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.